Lupin announced that the Food and Drug Administration (FDA) has granted final approval for Voriconazole Tablets and Oral Suspension, the generic version of Pfizer’s Vfend.
Vfend is an azole antifungal which inhibits fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylation, thereby contributing to the loss of ergosterol in the fungal cell wall. It is indicated for the treatment of susceptible fungal infections including invasive aspergillosis, candidemia in non-neutropenic patients, esophageal candidiasis, and candida infections of the abdomen, kidney, bladder, wounds, and disseminated skin. Vfend is also indicated for serious infections caused by Scedosporium apiospermum and Fusarium species in patients refractory to, or intolerant of, other agents.
Voriconazole Tablets will be available in 50mg and 200mg strengths. Voriconazole Oral Suspension will be available in a 40mg/mL dosage form.
For more information call (800) 399-2561 or visit Lupinpharmaceuticals.com.